Abstract
Abstract T cell checkpoint inhibitors are now standard of care for patients with triple negative breast cancer. Currently these agents are combined with combination cytotoxic chemotherapy. In this talk we will cover the composition of the immune infiltrate, rationale for T cell therapies, more or less chemotherapy and biomarkers of response and resistance. Citation Format: S. Loi. Current overview of immunotherapy in breast cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr SoA1-03.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
